Surrozen pauses PhI clinical trial in ulcerative colitis due to adverse events in liver

Just over a month after Wnt player Surrozen handed off its retinal disease candidate to Boehringer Ingelheim, the San Francisco biotech is reporting clinical issues on its end.

Per a Q3 report released Monday afternoon, Surrozen has decided to pause enrollment in the ascending dose portion of a Phase I...

Click to view original post